{Reference Type}: Journal Article
{Title}: Tri-aryl antimony(V) hydroximato and hydroxamato complexes: Combining lipophilic Sb(III/V) and hydroxamic acids in combating Leishmania.
{Author}: Soukup CRM;Duffin RN;Burke KJ;Andrews PC;
{Journal}: J Inorg Biochem
{Volume}: 260
{Issue}: 0
{Year}: 2024 Nov 26
{Factor}: 4.336
{DOI}: 10.1016/j.jinorgbio.2024.112674
{Abstract}: Six novel tri-aryl antimony(V) hydroximato complexes (3-8) with composition [SbAr3(O2NCR)] (3: Ar = Ph, R = o-(OH)Ph, 4: Ar = Ph, R = Me, 5: Ar = Ph, R = Ph; 6: Ar = Mes, R = Me, 7: Ar = Mes, R = Ph, 8: Ar = Mes, R = o-(OH)Ph (where Ph = phenyl, Me = methyl, Mes = mesityl)), were synthesised and evaluated for anti-parasitic activity towards Leishmania major (L. major) promastigotes and amastigotes. Complexes of the form [SbAr3(O2NCR)], with the dianionic hydroximato ligand binding O,O'-bidentate to the Sb(V) centre, exist in the solid-state for the mesityl-derived complexes. In contrast, the phenyl-ligated Sb(V) complexes crystallise as the hexacoordinate, hydroxamato species [SbPh3(O2NHC(OH))], with the OH ligand derived from entrained H2O in the crystallisation solvent. It is found that both the aryl and hydroximato ligands are found to influence the bioactivity of the Sb(V) complexes. Complexes 3-8 exhibited varied anti-promastigote activity with IC50 values ranging from 1.53 μM for 6 to 36.0 μM for 3, also reflected in varied anti-amastigote activity with a percentage infection range of 5.50% for 6 to 29.00% for 3 at a concentration of 10 μM. The complexes were relatively non-toxic to human fibroblasts with an IC50 value range of 59.3 μM (7) to ≥100 μM (3-6, 8), and exhibited varied toxicity towards J774.1 A macrophages (IC50: 3.97 (6) to ≥100 (8) μM). All complexes showed enhanced activity compared to the parent hydroxamic acids.